Group 1 - The Shenzhen Stock Exchange announced on December 8 that due to the adjustment of the Hang Seng Composite MidCap Index, the list of eligible securities for the Stock Connect program will be updated [1] - Four companies have been added to the Stock Connect program, effective from December 8, 2025: FWD Group (01828), Aux Group (02580), Sinopharm Group (02591), and Chery Automobile (09973) [1][3] Group 2 - The adjustment includes the addition of FWD Group, Aux Group, Sinopharm Group-B, and Chery Automobile to the Stock Connect program [3]

本文源自：财华网 【财华社讯】银诺医药-B(02591.HK)公布，根据上海证券交易所及深圳证券交易所分別发出的公告，公 司H股获纳入沪港通及深港通合资格证券名单，自2025年12月8日起生效。 ...

银诺医药-B(02591.HK)发布公告，根据上海证券交易所及深圳证券交易所分别发出的公告，本公司H股 (H股)获纳入沪港通及深港通(沪港通及深港通)合资格证券名单，自2025年12月8日起生效。 本文源自：金融界AI电报 ...

Core Viewpoint - The company, Silver Noble Pharmaceuticals-B (02591), has announced that its H-shares will be included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025, which is expected to enhance its investor base and trading liquidity [1] Group 1 - The inclusion of H-shares in the Stock Connect programs allows qualified investors from mainland China to directly invest in H-shares through the Shanghai and Shenzhen stock exchanges [1] - The board believes that this inclusion will further expand the company's investor base and increase the trading liquidity of H-shares [1] - The anticipated outcome is an enhancement of the investment value of H-shares and an improvement in the company's reputation in the capital markets [1]

格隆汇12月8日丨银诺医药-B(02591.HK)宣布，根据上海证券交易所及深圳证券交易所分别发出的公 告，公司H股获纳入沪港通及深港通合资格证券名单，自2025年12月8日起生效。 H股获纳入沪港通及深港通后，中国内地的合资格投资者可通过上海证券交易所及深圳证券交易所直接 投资H股。董事会认为，获纳入沪港通及深港通将进一步扩大公司的投资者基础及增加H股的交易流通 量，从而提升H股的投资价值及本公司於资本市场的声誉。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 自願性公告 獲納入滬港通及深港通證券名單 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東（「股東」）及有意投資者提供有關本公司最新進 展的資料。 滬港通及深港通為股票市場交易互聯互通機制。上海證券交易所、深圳證券交易 所及香港聯合交易所有限公司已建立技術連接，使中國內地及中華人民共和國香 港特別行政區的投資者可以通過當地證券公司或經紀買賣在對方證券交易所上市 的合資格股票。 1 本公司謹此感謝股東及投資者一直以來的支持。本公司將繼續努力發展業務，為 股東創造價值。 股東及有意投資者於買賣本公司證券時，務請審慎行事。 承董事會命 廣州銀諾醫藥集團股份有限公司 ...

Group 1 - The core viewpoint of the article highlights that SINO PHARMACEUTICAL (02591) experienced a significant decline of over 13% after a two-week cumulative increase of 50% in its stock price [1] - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] - The Shanghai and Shenzhen Stock Exchanges announced that SINO PHARMACEUTICAL will be included in the Hong Kong Stock Connect effective from December 8, 2025, due to adjustments in the Hang Seng Composite MidCap Index [1] Group 2 - SINO PHARMACEUTICAL's self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list on January 1, 2026 [1]

每经AI快讯，银诺医药-B(02591.HK)回吐逾13%，此前两周股价累计涨幅达50%。截至发稿，跌 13.64%，报38港元，成交额3031.07万港元。 （文章来源：每日经济新闻） ...

银诺医药-B(02591)回吐逾13%，此前两周股价累计涨幅达50%。截至发稿，跌13.64%，报38港元，成交 额3031.07万港元。 消息面上，上交所、深交所发布公告称，因恒生综合中型股指数实施成份股调整，根据有关规定，港股 通标的名单发生调整，将银诺医药调入港股通，自2025年12月8日起生效。此外，银诺医药宣布，公司 自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α（怡诺轻 ）正式纳入2025年国家医保药品目录，将 自2026年1月1日起与新版目录同步实施。 ...

Core Viewpoint - Silver诺医药-B (02591) experienced a decline of over 13% after a significant increase of 50% in the previous two weeks [1] Group 1: Stock Performance - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the Hang Seng Composite MidCap Index, resulting in Silver诺医药 being included in the Hong Kong Stock Connect list, effective from December 8, 2025 [1] Group 3: Product Development - Silver诺医药's self-developed long-acting GLP-1 receptor agonist, Eysuparaglutide α (怡诺轻®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list starting January 1, 2026 [1]